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ABSTRACT
Cardiovascular disease (CVD), including heart
failure (HF), is a leading cause of morbidity and
mortality in people with type 2 diabetes melli-
tus (T2DM). CVD and T2DM share common risk
factors for development and progression, and
there is significant overlap between the condi-
tions in terms of worsening outcomes. In
assessing the cardiovascular (CV) safety profiles
of anti-diabetic drugs, sodium-glucose co-
transporter-2 inhibitor (SGLT2i) therapies have
emerged with robust evidence for reducing the
risk of adverse CVD outcomes in people with
T2DM who have either established CVD or are
at risk of developing CVD. A previous consensus
document from the Improving Diabetes Steer-
ing Committee has examined the potential role
of SGLT2is in T2DM management and consid-
ered the risk–benefit profile of the class and the
appropriate place for these medicines within
the T2DM pathway. This paper builds on these
findings and presents practical guidance for
maximising the pleiotropic benefits of this class
of medicines in people with T2DM in terms of
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reducing adverse CVD outcomes. The Improv-
ing Diabetes Steering Committee aims to offer
evidence-based practical guidance for the use of
SGLT2i therapies in people with T2DM stratified
by CVD risk. This is of particular importance
currently because some treatment guidelines
have not been updated to reflect recent evi-
dence from cardiovascular outcomes trials
(CVOTs) and real-world studies that comple-
ment the CVOTs. The Improving Diabetes
Steering Committee seeks to support healthcare
professionals (HCPs) in appropriate treatment
selection for people with T2DM who are at risk
of developing or have established CVD and
examines the role of SGLT2i therapy for these
people.
Funding: Napp Pharmaceuticals Limited.
Keywords: Anti-diabetic medicines; Cardio-
vascular disease (CVD); Clinical guidance;
Heart failure (HF); Oral glucose-lowering medi-
cines; Practical treatment selection; SGLT2
inhibitors (SGLT2i); Therapy choice; Type 2
diabetes mellitus (T2DM)
THE ROLE OF THE IMPROVING
DIABETES STEERING COMMITTEE
The Improving Diabetes Steering Committee
comprises a panel of clinical experts from across
primary and specialist care, who meet with the
objective of improving diabetes care. The
Committee aims to ensure that HCPs who pre-
scribe diabetes medicines have access to bal-
anced and accurate information and evidence
concerning type 2 diabetes mellitus (T2DM)
medicines, with a specific focus on the
sodium–glucose co-transporter-2 inhibitor
(SGLT2i) class of treatments. The group is
committed to providing healthcare colleagues
with clarity concerning the evidence base sup-
porting SGLT2i agents, highlighting the relative
benefits and risks of these therapies. Educa-
tional materials and publications, such as the
previous consensus document [1], provided by
the panel are intended to increase confidence
and understanding regarding the appropriate
place of these medicines within the current UK
T2DM treatment paradigm. Due to the nature of
the Committee, this article and related discus-
sions are based on previously conducted studies
and does not contain any studies with human
participants or animals performed by any of the
authors.
TAKING TYPE 2 DIABETES OUT
OF ISOLATION: THE IMPACT
OF CARDIOVASCULAR DISEASE
People with T2DM commonly live with multi-
ple comorbidities, among which hypertension
and cardiovascular disease (CVD) are the most
common [2]. A systematic review of global
clinical records from over 4.5 million people
with T2DM (median duration 10 years)
observed that CVD was a comorbidity in
approximately one third of people with T2DM;
of those, 29.1% had atherosclerosis, 21.2% had
coronary heart disease (CHD), 14.9% had heart
failure (HF), 14.6% had angina, 10.0% had had
a myocardial infarction (MI) and 7.6% had
experienced stroke [3]. A recent cohort study,
utilising data from the UK Clinical Practice
Research Datalink, found a similar prevalence of
these conditions in over 1.5 million people with
T2DM in the UK [4]. In people with T2DM,
elevated risk of peripheral arterial disease,
ischaemic stroke, stable angina, HF and non-
fatal MI was observed; there was no associated
increased risk of arrhythmia or sudden cardiac
death and an inverse relationship with abdom-
inal aortic aneurysm and subarachnoid haem-
orrhage [4]. The fact that a large proportion of
people with T2DM who are managed in routine
practice have concomitant CVD raises the
important question of whether it is effective to
treat people by addressing each disease in iso-
lation, or whether a holistic, personalised
approach that takes shared risk factors into
account can contribute to improved outcomes.
Overall, CVD is associated with significant
morbidity and mortality in people living with
T2DM, and may account for as many as half
(50.3%) of deaths in this population [3]. This is
markedly higher than the global mortality rate
for CVD of 31% [5].
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The burden of CVD in T2DM is considerable,
both for people living with comorbid condi-
tions and for the healthcare systems that sup-
port them. Globally, comorbid CVD contributes
to 20–49% of the total cost of managing T2DM
[6]. Compared with treating T2DM without
CVD, median annual costs are 112% higher
with CVD, 107% higher with coronary artery
disease (CAD), 59% higher with HF and 322%
higher with stroke [6].
Efficacious management of CVD risk and
disease in people with T2DM is therefore a pri-
ority for both the individuals affected and for
healthcare systems more broadly.
THE RELATIONSHIP BETWEEN
TYPE 2 DIABETES AND
CARDIOVASCULAR DISEASE:
COMMON FACTORS
T2DM and CVD share risk factors for the onset
and worsening of disease [7]. The common
pathophysiological processes include insulin
resistance, chronic systemic inflammation,
hypercoagulability, elevated blood pressure,
dyslipidaemia and obesity [7–9]. Moreover, the
presence of hyperglycaemia, which defines
T2DM, is an independent risk factor for CVD
[9]. Obesity is recognised as a risk factor for CVD
and HF, and contributes to the development of
insulin resistance [10–12]. In many cases, insu-
lin resistance develops prior to onset of hyper-
glycaemia in T2DM, and both of these disorders
increase the risk of developing CVD [13, 14].
Insulin resistance is therefore a key driver in the
pathogenesis of CVD in people who present
with HbA1c levels below the threshold for a
diagnosis of type 2 diabetes. Increasing insulin
resistance and consequent dysglycaemia should
be recognised as risk factors for CVD; a study in
nearly 12,000 patients without a history of
diabetes demonstrated that asymptomatic
hyperglycaemia was associated with higher risk
of CV death compared with patients with low
post-load glucose levels [15–17].
Insulin resistance is also involved in a com-
plex interplay with multiple metabolic func-
tions, and contributes to the pathophysiology
of hypertension and dyslipidaemia [18]. Dia-
betic dyslipidaemia has been identified as an
independent risk factor for CHD and stroke
[19, 20].
These overlapping risk factors are common,
which is reflected in the fact that a relatively
high proportion ([ 20%) of people with T2DM
who are treated by HCPs in primary care have
concomitant CVD [21].
HEART FAILURE: A NEW FOCUS
FOR CARDIOVASCULAR DISEASE
IN DIABETES
Previously, considerations around CV outcomes
in people with T2DM have focused on the
incidence of stroke, MI and CV death, which
reflects the endpoints of the atherosclerotic
disease process [22, 23]. These three outcomes
are commonly combined into a study endpoint
called 3-point Major Adverse CV Events (3P-
MACE) [23]. Historically, HF is one of the most
common and earliest presenting CV complica-
tions, and may develop independently of
atherosclerosis [4, 22, 24]. Overall, 35–45% of
patients with chronic HF have T2DM [22], and
diagnosis of HF is the first CV event in around
14% of people with T2DM [4]. Compared with
the general population, the relative risk (RR) of
developing HF in people with T2DM is twofold
higher for men and fivefold higher for women
[25]. Prior to the studies discussed below, HF
was not included in primary outcome evalua-
tions of cardiovascular outcomes trials (CVOTs)
in T2DM [26, 27]. The criteria for diagnosing HF
have been inconsistent across clinical trials and
baseline diagnosis of HF was not independently
adjudicated in CVOTs; however, in the SGLT2i
CVOT endpoint data presented here, HF was
blindly adjudicated using criteria that are used
in HF studies. The prevalence of people with
T2DM with comorbid HF in primary care man-
agement is relatively common ([ 22% of
patients) [21]; it has also been recognised that
HF may be underdiagnosed in routine care
[28, 29].
Insulin resistance and hyperglycaemia are
common factors in the development of both
T2DM and HF, along with advancing age and
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inflammation [22, 30, 31]. Hyperglycaemia and
insulin resistance are associated with multiple
adverse metabolic effects; people with diabetes
have elevated levels of free fatty acids that
require high oxygen consumption to metabo-
lise, potentially impacting myocardial perfor-
mance, and leading to intracellular
accumulation of toxic intermediate products
[32]. Hyperglycaemia may also drive increased
oxidative stress, damaging the myocardium,
reducing antioxidant defence and contributing
to endothelial dysfunction [32]. Morphological
changes in the heart may be triggered by accu-
mulation of advanced glycation end products in
people with hyperglycaemia, leading to a loss of
blood vessel elasticity; furthermore, hypergly-
caemia may be associated with necrosis of
myocytes, which leads to deposition of collagen
and myocardial fibrosis [32]. In people without
diabetes, HF risk increases if haemoglobin A1c
(HbA1c) is above 5.5%, and a 1% increase in
HbA1c is associated with a 39% increase in HF.
In T2DM, the risk of HF rises by 8–32% per 1%
increase in HbA1c [33]; thus HF risk appears to
be associated with HbA1c in those with and
without diabetes, independent of other risk
factors. Development of HF in people with
T2DM is associated with significantly greater
mortality than in those with T2DM who do not
develop HF [34].
It has also been demonstrated that HF is a
risk factor for the development of T2DM. Over
7.7 years of follow-up, T2DM developed across
New York Heart Association (NYHA) severities
I–III of HF: 17% of patients in class I, 15% in
class II and 20% in class III (P for trend = 0.05).
There was a twofold increase in likelihood of
having fasting blood glucose of at least 7 mmol/
L in patients with more severe HF (NYHA class
III [17%] versus class I [7.8%] or II 8.7%]) [35].
This bidirectional relationship between
T2DM and HF in terms of disease risks and
progression highlights the need for a selection
of effective treatment strategies in routine
practice that recognise both diseases. There is
also an increasing burden of HF: in a study of 4
million patient records in the UK between 2002
and 2014, there was an estimated increase of
12% in individuals with newly diagnosed HF
and a 23% estimated increase in the number of
prevalent HF cases [36]. This trend highlights a
need for a more effective strategy to prevent and
manage HF in people with T2DM.
THE ROLE OF GLYCAEMIC
CONTROL IN MANAGING
CARDIOVASCULAR RISK IN PEOPLE
WITH TYPE 2 DIABETES
Management of CV risk factors, including glu-
cose, plays a key role in the treatment of people
with T2DM. Meta-analyses of long-term studies
have demonstrated the benefits of reducing
HbA1c on CV outcomes [37, 38]. Retrospective
analysis of the UK Prospective Diabetes Study
(UKPDS) observed lower RR of stroke (12%;
P = 0.035), MI (14%; P\0.0001) and HF (16%;
P = 0.021) per 1% reduction in HbA1c [38].
However, microvascular outcomes (37%
decrease per 1% HbA1c; P\0.0001) were
improved to a greater extent with glycaemic
control than macrovascular outcomes [38], and
reducing HbA1c alone has less benefit in
reducing risk or incidence of MI, stroke and
CVD than reducing blood pressure (BP) or
improving lipid management [39].
Benefit may be obtained with a ‘treat-to-tar-
get’ approach for HbA1c in the management of
CHD, because a close correlation between the
risk of CHD and increasing HbA1c has been
observed. In a prospective study of 1626 people
with T2DM and 1321 people without diabetes,
the RR of CHD increased by 1.14 (95% confi-
dence interval [CI] 1.07–1.21) per percentage
point increase in HbA1c, across all HbA1c val-
ues, and RR increased by 2.36 (95% CI
1.43–3.90) per percentage point in patients
without diabetes but with an HbA1c of more
than 4.6% [40]. Similar increases in the RR of
CHD per percentage point increase in HbA1c
were seen in a large prospective trial of nearly
30,000 people with T2DM, across a range of
baseline HbA1c values and independent of age,
sex and smoking history [41]. For patients with
renal disease, meta-analysis of tight glycaemic
control has been associated with delayed onset
of microalbuminuria (4 studies, 19,846 partici-
pants: RR 0.82, 95% CI 0.71–0.93) and
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progression of microalbuminuria (5 studies,
13,266 participants: RR 0.59, 95% CI 0.38–0.93),
although there was less certain evidence for
effect on progression to end-stage kidney dis-
ease [42].
However, there is a limit to the effectiveness
of targeting glycaemic control alone, using tra-
ditional anti-diabetic medications for the man-
agement of CVD and HF [43, 44]. In addition,
there are cautionary notes in the aggressive
pursuit of lower HbA1c. No significant benefits
were observed with intensive treatment of
hyperglycaemia in the Action to Control Car-
diovascular Risk in Diabetes (ACCORD; target-
ing an HbA1c below 6.0%) study [45], the
Action in Diabetes and Vascular Disease: Pre-
terax and Diamicron MR Controlled Evaluation
(ADVANCE; targeting an HbA1c below 6.5%)
study [46] or the Veterans Affairs Diabetes Trial
(VADT; median HbA1c of 6.9%) [47]. Notably,
the ACCORD study reported a significant 22%
increase [hazard ratio (HR) 1.22; 95% CI
1.01–1.46; P = 0.04] in total deaths in the
intensively treated group compared with pla-
cebo [45]. Until the recent CVOT findings,
metformin was the only diabetes therapy asso-
ciated with a lower rate of all-cause mortality in
people with T2DM and HF, compared with
combinations with sulfonylurea or insulin
therapy [48].
Given that T2DM is associated with inde-
pendent risk factors for CVD, considerations
beyond just elevated HbA1c need to be
accounted for when developing management
strategies [9]. Appropriate, early intervention is
needed to improve CV outcomes in people with
T2DM, with treatment goals beyond achieving
glycaemic control alone.
When treating T2DM in a person with
comorbidities, especially one at risk of CVD,
HCPs need to consider a personalised approach
that achieves glucose lowering and reduces CV
risk factors [49]. Recent CV outcomes studies
have demonstrated cardiovascular benefits in
people receiving an SGLT2i therapy for the
management of T2DM [50–56].
WHY MIGHT SGLT2I TREATMENTS
INFLUENCE CARDIOVASCULAR
OUTCOMES?
The mechanisms by which SGLT2is provide the
benefits that have been observed in recent
studies remain to be elucidated. Biomarkers and
surrogate endpoints measured in these trials
demonstrate that SGLT2 inhibition modifies
many risk factors for CVD, beyond glucose
levels, including BP, weight, visceral adiposity,
hyperinsulinaemia, arterial stiffness, albumin-
uria, circulating uric acid levels and oxidative
stress [57, 58]. These factors are implicit in
multiple pathways related to cardiorenal out-
comes; SGLT2i treatments modulate natriuresis
and glycosuria—excretion of sodium and glu-
cose—which modify the factors in these path-
ways (Fig. 1) [58].
In the context of SGLT2 inhibition, there is
considerable overlap between these factors; for
example, SGLT2i-induced BP lowering may be
associated with reduced arterial stiffness, natri-
uresis and weight loss. Reduction in weight and
visceral fat deposition is most likely linked to
glycosuria and consequent negative energy
balance. Arterial stiffness has been linked to
obesity, hypertension and hyperglycaemia.
Thus, synergistic modulation of these factors
via SGLT2 inhibition is proposed to play a sig-
nificant role in the reduction of risk for the
development of CVD [57, 58].
Several mechanisms of action have been
proposed to explain the benefits of SGLT2i
agents on the heart. To date, none of the pro-
posed mechanisms have been able to unequiv-
ocally explain the CV benefit demonstrated in
randomised clinical trials (RCTs). SGLT2 inhi-
bition may improve cardiac metabolism and
bioenergetics by elevating the production of
ketones, which represent a more efficient
myocardial energy source than fatty acids and
which require less oxygen to metabolise, con-
sequently improving myocardial oxygen effi-
ciency. The myocardium is less flexible in its use
of available energy sources when stressed by
diabetes or HF, and this increased availability of
ketones may allow for more efficient cardiac
function [59]. In addition, the
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haemoconcentration that is typically induced
by SGLT2 inhibition may result in improved
tissue oxygen delivery, and a potential syner-
gistic effect with the myocardial metabolic
substrate shift [60]. More favourable ventricular
loading conditions may also arise from reduced
arterial stiffness and BP, as a result of this
osmotic diuresis and natriuresis [59]. Finally,
SGLT2 inhibition may inhibit the Na?/H?
exchanger (NHE)-1 isoform in the myocardium,
activation of which has been associated with
elevated sodium and calcium levels in experi-
mental models of HF [59]. Further investigation
into the potential roles of modified cardiac
fibrosis and cytokine production with SGLT2i
treatment is underway [59].
It has been hypothesised that HF outcomes
may be most sensitive to SGLT2i treatments.
While atherosclerotic CVD (ASCVD) mecha-
nisms may also be affected by SGLT2i treatment
Fig. 1 Proposed pathways involved in cardioprotective role of SGLT2is. Multiple physiologic mechanisms related to
cardiorenal outcomes are modulated with SGLT2i treatments. Adapted with permission from [58]
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[59], the fact that a significant improvement in
3P-MACE was not achieved in the recent
DECLARE-TIMI 58 study points to a tenuous
link between ASCVD and SGLT2 inhibition in
clinical outcomes [52]. However, the beneficial
effect of SGLT2 inhibition on improving HF
outcomes has been consistent [50–52].
SGLT2i treatments also appear to have posi-
tive renal benefits in reducing the rate of albu-
minuria progression and a reduced worsening of
nephropathy. These benefits are postulated to
arise from the restoration of tubuloglomerular
feedback, which is a key mechanism in the
kidney for the regulation of glomerular filtra-
tion rate (GFR) [61]. Other mechanisms,
including amelioration of intrarenal hypoxia
and subsequent anti-inflammatory effects have
also been proposed.
Although SGLT2i treatments have a reduced
glucose-lowering effect in people with reduced
renal function, the renal benefits of SGLT2i
agents appear to be preserved among people
both with and without chronic kidney disease
(CKD); these benefits include significant reduc-
tion in albuminuria and reduced incidence of
worsening albuminuria [62, 63]. The benefits on
CVD outcomes with empagliflozin and cana-
gliflozin have been demonstrated in patients
with a range of baseline renal function capaci-
ties and across a range of urine albumin–crea-
tinine ratios; the effects of dapagliflozin were
similarly observed across a range of baseline
eGFR values [5, 52, 64, 65]. Currently, SGLT2i
treatment is indicated for initiation in people
with T2DM and an eGFR C 60 mL/min/1.73 m2
and should be discontinued if eGFR persistently
falls below 45 mL/min/1.73 m2 [66–68]. The
preserved efficacy of SGLT2 inhibition across a
range of degrees of renal impairment may be of
importance in treatment selection for people
with T2DM, because CKD and T2DM are both
associated with increased CV risk.
The efficacy of SGLT2i treatment will be
further elucidated in the forthcoming Canagli-
flozin and Renal Endpoints in Diabetes with
Established Nephropathy Clinical Evaluation
(CREDENCE) trial (unpublished at time of paper
development), which will prospectively assess
the efficacy and safety of canagliflozin in clini-
cally important renal and CV outcomes [69].
The primary composite endpoint is time to end-
stage kidney disease (ESKD), doubling of serum
creatinine, and renal or CV death. At a planned
interim analysis, the CREDENCE study demon-
strated efficacy in achieving this primary end-
point and as a result the trial was stopped early
[70]. Secondary endpoints include a CV com-
posite endpoint of CV death, non-fatal MI, non-
fatal stroke, hospitalisation for chronic HF and
hospitalisation for unstable angina [69].
WHAT EVIDENCE EXISTS
FOR THE MANAGEMENT OF CVD
RISK IN T2DM TREATMENT
WITH SGLT2I AGENTS?
For the past decade, there has been a regulatory
requirement for new drugs intended for the
treatment of T2DM to demonstrate that they
‘do not increase CV risk to an unacceptable ex-
tent’ and that phase III trials should include
endpoints for non-fatal MI, stroke and CVD
mortality [71]. This stipulation followed the
suggestion that rosiglitazone was associated
with a significant increase in the risk of MI and
a borderline significant increase in CV death
[72]. Following the requirement for anti-dia-
betic drugs to demonstrate that they do not
increase CV risk, several cardiovascular outcome
trials have been conducted and reported. Four
trials with dipeptidyl peptidase-4 (DPP-4) inhi-
bitors showed CV safety but no CV benefits
[73–76]. Several meta-analyses suggested a pos-
sible increased risk of acute HF or hospitalised
heart failure (HHF) with certain DPP-4 inhibi-
tors versus placebo; however more research is
required to explore these observations [77, 78].
In the glucagon-like peptide-1 receptor agonist
(GLP-1 RA) class, four drugs have demonstrated
significant improvements in CV safety out-
comes versus placebo (liraglutide, semaglutide,
albiglutide, dulaglutide) [79–82] and two have
not (exenatide and lixisenatide) [83, 84]. To
date, all three marketed SGLT2i medications
have demonstrated benefits beyond glycaemic
control, providing reductions in measures of
CVD across populations with varying risk for, or
degrees of, pre-existing CVD [50–52].
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The Improving Diabetes Steering Committee
has already commented on the risk–benefit
considerations and the practical implications of
the broad data from each pivotal SGLT2i trial
available at the time of publication: EMPA-REG
OUTCOME and Canagliflozin Cardiovascular
Assessment Study (CANVAS); subsequently the
Dapagliflozin Effect on CardiovascuLAR Events
(DECLARE-TIMI 58) trial has provided addi-
tional data particularly for those at lower risk of
CVD [1].
Here, the Committee considers the available
evidence in the context of maximising benefit
for people with T2DM and risk of CVD, with
informed treatment selection and management
strategy. A summary of study populations and
selected endpoints is shown in Fig. 2.
EMPA-REG OUTCOME examined the effi-
cacy and safety of empagliflozin 10 mg or
25 mg, compared with placebo, in addition to
standard of care. The trial enrolled 7020 people
with T2DM at high risk for CVD outcomes—all
participants had established CVD [50]. EMPA-
REG OUTCOME reported a 14% relative risk
reduction (RRR) in the 3P-MACE primary
outcome versus placebo (HR 0.86; 95.02% CI
0.74–0.99; P = 0.04 for superiority), a 38% RRR
in CV deaths (HR 0.62; 95% CI 0.49–0.77;
P\ 0.001), a 35% RRR for HHF (HR 0.65; 95%
CI 0.50–0.85; P = 0.002) and a 32% RRR in all-
cause mortality (HR 0.68; 95% CI 0.57–0.82,
P\ 0.001) [50]. The study observed no signifi-
cant differences between empagliflozin and
placebo in MI reports (4.8% and 5.4%, respec-
tively) or stroke incidence (3.5% and 3.0%,
respectively) [50].
These findings were expanded in a sub-
analysis of EMPA-REG OUTCOME, which
examined outcomes in people with T2DM and
confirmed CVD but differing HF status in those
with and without HF at enrolment [85]. Empa-
gliflozin reduced the rate of HHF in people
stratified as low-to-average risk (5-year HF
occurrence\10%), high risk (10–20%) and very
high risk ([20%), compared with placebo. Risk
of CV mortality was similarly reduced in people
with T2DM either with HF (HR 0.67 [0.47–0.97])
or without HF burden (HR 0.63 [0.48–0.84]) at
baseline [85]. This study noted that in people
with T2DM and established CVD, there was a
At a glance: Summary of different patient populations in each pivotal SGLT2i CVOT.
The populations in EMPA-REG, the CANVAS programme and DECLARE-TIMI 58 
differed in terms of what proportion of people had existing symptomatic CVD and what 
proportion did not have established CVD but were at risk of developing it [50–52].
- In EMPA-REG, all participants had established CVD.
- In the CANVAS trials, 65.6% of participants had established CVD and 34.4% 
had multiple risk factors.
- In DECLARE-TIMI 58, 40.6% of participants had established CVD and 59.4% 
had multiple risk factors.
These differences in populations may lead to different magnitudes of efficacy (a larger 
reduction in outcomes may be expected in a population with existing disease 
compared with a subpopulation without existing disease). DECLARE-TIMI 58 also had 
a relatively lower proportion of patients with more severe CVD, representing a 
population at lower risk of CVD and renal outcomes. However, insights into these 
populations can help inform the role of SGLT2i medications in primary and secondary 
prevention of CVD.
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high risk of mortality with baseline or incident
HF (15.3% in placebo) compared with people
with no HF burden (4.2% in placebo) [85]. Fur-
ther analysis has observed that the primary
endpoint benefits with empagliflozin were
observed over a range of baseline HbA1c values
and levels of renal function [86].
CANVAS examined the efficacy and safety of
canagliflozin 100 mg or 300 mg, compared with
placebo, in addition to standard of care. The
trial enrolled 10,142 people (across CANVAS
and CANVAS-renal [CANVAS-R]) with T2DM,
either with prior symptomatic CV events or at
least two risk factors for CVD [51, 65]. CANVAS
demonstrated a 14% RRR in the 3P-MACE pri-
mary outcome versus placebo (HR 0.86; 95% CI
0.75–0.97; P = 0.02 for superiority). A sub-anal-
ysis assessing HF reported that, compared with
placebo, canagliflozin was associated with a
significantly lower risk of composite CV death
or HHF (HR 0.78; 95% CI 0.67–0.91), as was fatal
or HHF (HR 0.70; 95% CI 0.55–0.89) or HHF
alone (HR 0.67; 95% CI 0.52–0.87) [87].
Pre-specified sub-analysis of the primary
endpoint by pre-existing disease observed an
RRR of 18% in people with a history of CVD (HR
0.82; 95% CI 0.72–0.95), reflecting benefit in a
more comparable patient population to EMPA-
REG [51].
DECLARE-TIMI 58 examined the efficacy
and safety of dapagliflozin 10 mg, compared
with placebo, in addition to standard of care.
The trial enrolled 17,160 people with T2DM
who either had previous CVD or no established
CVD and with multiple risk factors for the
development of CVD—this latter population
accounted for 10,186 of the participants
[52, 88]. DECLARE-TIMI 58 had two co-primary
efficacy analyses: 3P-MACE and composite HHF
and CV death. Dapagliflozin did not reduce 3P-
MACE rate (8.8% with dapagliflozin versus 9.4%
with placebo; HR 0.93; 95% CI 0.84–1.03;
Fig. 2 Overview of trial population and selected cardio-
vascular endpoints in SGLT2i CVOTs [50–52]. This
ﬁgure reports selected outcomes from three trials of an
active comparator versus placebo in addition to standard of
care, and is not a head-to-head trial outcome. 3P-MACE
3-point major adverse cardiovascular events, CI conﬁdence
interval, CVD cardiovascular disease, CVOT cardiovascu-
lar outcomes trials, HHF hospitalisation for heart failure,
HR hazard ratio
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P = 0.17). Dapagliflozin did result in a lower rate
of CV death or HHF versus placebo (4.9% versus
5.8%; HR 0.83; 95% CI 0.73–0.95; P = 0.005).
This reduction in composite rate reflected a
lower rate of HHF alone (HR 0.73; 95% CI
0.61–0.88); there was no difference between
dapagliflozin and placebo in rate of CV death
(HR 0.98; 95% CI 0.82–1.17) [52]. In a subgroup
of patients with existing CVD, 3P-MACE was
reduced to a greater extent than in the overall
DECLARE-TIMI 58 population, although the
improvement was still not statistically signifi-
cant (HR 0.90; 95% CI 0.79–1.02); this subgroup
of patients is more comparable to the EMPA-
REG trial population [52]. In patients with prior
MI, dapagliflozin was associated with a 16%
RRR in 3P-MACE and a 2.6% absolute risk
reduction versus placebo (15.2% versus 17.8%;
HR 0.84; 95% CI 0.72–0.99; P = 0.039); there
was no difference in MACE reduction in people
without a prior MI [89].
Dapagliflozin was associated with improve-
ment in the composite renal secondary end-
point (C 40% eGFR reduction to\ 60 mL/min
per 1.73 m2, end-stage renal disease, or renal or
CV death) compared with placebo (events in
4.3% versus 5.6% of each arm, respectively; HR
0.76; 95% CI 0.67–0.87) [52]. However, the
Committee notes that care should be taken in
extrapolating these data because formal statis-
tical analysis of this endpoint ceased once the
primary MACE endpoint was not met.
These pivotal RCTs have demonstrated CVD
or HF benefits with SGLT2i therapies in people
with T2DM and at high risk of CVD. However, it
is important to remember that these studies
have highly selective populations to enable the
study to be conducted under the carefully con-
trolled conditions often necessary for statistical
calculations, and many people who may be
eligible for an SGLT2i in routine practice are
excluded [90]. Real-world evidence (RWE) can
complement RCT data and support HCPs in
decision-making for the appropriate treatment
of their patients.
BROADENING THE EVIDENCE BASE:
THE ROLE OF REAL-WORLD
EVIDENCE IN INFORMING
TREATMENT DECISIONS
Real-world studies have the advantage of
observing the safety and efficacy of drugs in
Update on SGLT2i safety outcomes
The Improving Diabetes Steering Committee has already commented on safety data 
from EMPA-REG OUTCOME and CANVAS [1] .Since the publication of that document, 
DECLARE-TIMI 58 has released its safety data set. 
Recent safety findings for dapagliflozin versus placebo included a higher rate of 
genital infections (0.9% of study population versus 0.1% with placebo; P < 0.001), but 
no significant safety signal concerning fractures (5.3% versus 5.1%; P = 0.59), 
amputation (1.4% versus 1.3%; P = 0.53), or urinary tract infection (1.5% versus 1.6%; 
P = 0.54). Acute kidney injury was notably less frequent with dapagliflozin-treated 
people (1.5% versus 2.0%; P = 0.002). Diabetic ketoacidosis was more common with 
dapagliflozin than with placebo (0.3% versus 0.1%, P = 0.02) [51]. Fournier’s gangrene 
was rare, with one case in the dapagliflozin arm and five cases with placebo. Given 
the considerable differences in patient populations in EMPA-REG, CANVAS and 
DECLARE-TIMI 58, especially considering relative rates of previous disease and 
events (0.6% of participants in DECLARE-TIMI 58 had previous amputations, 
compared with 2.3% in CANVAS) [51,84],care will need to be taken in interpreting and 
generalising safety signals. These updates have been reflected in the prescribing tool 
previously developed by the Improving Diabetes Steering Committee, and updated in 
April 2019   .[1]
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broader populations that are more representa-
tive of the people most likely to be prescribed
the studied drugs in daily clinical practice
(Fig. 3) [91]. Real-world studies facilitate the
confirmation of RCT findings against observa-
tions in routine clinical practice and can
therefore help increase the external validity and
generalisability of RCT data. RWE also has lim-
itations: data capture is performed in an
uncontrolled setting, which is less robust than
in an RCT environment, and real-world studies
may be more prone to, and less able to adjust
for, confounding data than RCTs [92, 93].
Importantly, RWE can provide insight into
how a drug performs in the real-world treat-
ment of people and these findings, often in
large study populations, can support HCPs in
making appropriate, evidence-based, therapy
choices. This is of particular relevance when
considering benefits beyond glucose control, as
the people observed in real-world studies will
have typical comorbidities and concomitant
treatments that may have resulted in them
being excluded from RCTs [91].
SGLT2I TREATMENTS IN ROUTINE
PRACTICE: REAL-WORLD EVIDENCE
FOR CARDIOVASCULAR BENEFITS
IN PEOPLE WITH TYPE 2 DIABETES
Three large recent real-world studies have
observed the CV benefits of SGLT2i treatments
in typical people with T2DM. In total, these
studies provide RWE on outcomes in over one
million people with T2DM. Furthermore, these
studies examine outcomes similar to those
reported in the RCTs described earlier. These
Fig. 3 Population characteristics of different types of
therapeutic trial. Real-world observational evidence com-
plements prospective data from randomised controlled
trials by examining the safety and efﬁcacy of drugs in a
broader population that is representative of people most
likely to use the drug [91]. RCT randomised controlled
trial. Reprinted with permission of the American Thoracic
Society Copyright  2019 American Thoracic Society.
Roche et al. [91]. Annals of the American Thoracic Society
is an ofﬁcial journal of the American Thoracic Society
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studies also provide insight into class trends in
outcomes with SGLT2is, which can support
HCP decision-making. A summary of study
populations and selected endpoints is shown in
Fig. 4.
The Evidence for Cardiovascular Outcomes
with Sodium Glucose Cotransporter-2 Inhibi-
tors in the Real World (EASEL) study followed a
propensity-matched population of 25,258 peo-
ple with T2DM and established CVD for a mean
duration of 1.6 years. EASEL assessed the bene-
fits of SGLT2i compared with non-SGLT2i
treatments. In the cohort prescribed an SGLT2i
treatment, 58.1% received canagliflozin, 26.5%
received empagliflozin and 15.4% received
dapagliflozin [56]. For its primary composite
endpoint (HHF and all-cause mortality), EASEL
reported a lower event rate in SGLT2i-treated
people than those treated with non-SGLT2i
therapies [1.73 versus 3.01 events per 100 per-
son-years (HR 0.57; 95% CI 0.50–0.65)]. The
SGLT2i-treated cohort, compared with the non-
SGLT2i-treated cohort, also had better out-
comes for all-cause mortality rate [1.29 versus
2.26 events per 100 person years (HR 0.57; 95%
CI 0.49–0.66; P\ 0.0001)], HHF [0.51 versus
0.90 events per 100 person years (HR 0.57, 95%
CI 0.45–0.73; P\0.0001)] and MACE [2.31
versus 3.45 events per 100 person years (HR
0.67; 95% CI 0.60–0.75)] [56].
The CVD-REAL study followed a propensity-
matched population of 309,056 people with
T2DM, newly initiated on either an SGLT2i
agent or ‘other glucose-lowering drugs’ (oGLD)
for 374 days in the SGLT2i-treated cohort and
392 days in the oGLD cohort. CVD-REAL
reported that SGLT2i treatment, versus oGLD in
people with T2DM either with (13% of the
matched population) or without established
CVD, was associated with lower risk of HF (HR
0.72; 95% CI 0.62–0.83 and HR 0.61; 95% CI
0.48–0.78, respectively) and composite HF and
death (HR 0.63; 95% CI 0.57–0.07 and HR 0.56;
95% CI 0.50–0.62, respectively). There was a
reduction in overall death in people with
T2DM, with or without pre-existing CVD (HR
0.56; 95% CI 0.44–0.70 and HR 0.56; 95% CI
0.50–0.63, respectively) [53]. In CVD-REAL 2,
27% of participants had established CVD [54].
Compared with oGLD therapy, SGLT2i treat-
ment was associated with lower rates of HHF
(HR 0.64; 95% CI 0.50–0.82; P\0.001), death
(HR 0.51; 95% CI 0.37–0.70; P\0.001), MI (HR
0.81; 95% CI 0.74–0.88; P\0.001) and stroke
(HR 0.68; 95% CI 0.55–0.84; P\ 0.001) [53, 54].
CVD-REAL Nordic assessed the benefits of
dapagliflozin compared with DPP-4 inhibitors
in 40,908 propensity-matched people (23%
with established CVD), newly initiated on
treatment, with a follow-up of 0.95 years.
Dapagliflozin was associated with a lower risk of
MACE (HR 0.79; 95% CI 0.67–0.94) and HHF
(HR 0.62; 95% CI 0.50–0.77) compared with the
DPP-4 inhibitor group. Compared with DPP-4
inhibitor therapy, dapagliflozin was associated
with non-significantly lower risk of non-fatal
MI, non-fatal stroke and CV mortality [94].
The value of propensity score matching
Propensity score matching allows differences in outcomes between compared 
treatments to be observed as objectively as possible. 
Propensity score matching is a tool used in the retrospective statistical analysis of 
real-world evidence to minimise the number of variables that may affect an 
observation. In studies that enrol large numbers of people with heterogenous diseases 
and multiple comorbidities, propensity score matching is used to match a patient in the 
treatment group as closely as possible to a patient in the comparator group across as 
many different variables as possible (e.g. age, sex, BMI, duration of disease(s), 
previous medication, etc.) This process increases the certainty with which any 
observed differences in outcome can be assigned to the different interventions, and 
not to confounding factors.
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OBSERVE 4-D examined outcomes in
142,800 new users of canagliflozin, 110,897 new
users of other SGLT2i agents and 460,885 new
users of non-SGLT2i therapies in a retrospective
cohort analysis using observational databases,
with a relatively short follow-up of 60–100 days.
Of the subgroup of participants with established
CVD, 43,043 were new users of canagliflozin,
31,011 were new users of other SGLT2i and
141,579 were new users of non-SGLT2i thera-
pies [55]. OBSERVE 4-D reported that canagli-
flozin was associated with a reduction in HHF
risk compared with non-SGLT2i medicines (HR
0.39; 95% CI 0.26–0.60; P = 0.01); there was no
difference in risk reduction between canagli-
flozin and other SGLT2i agents (on-treatment
HR 0.70; 95% CI 0.30–1.63) [55].
A recent analysis noted that while the abso-
lute values and magnitude of treatment effects
will differ to some degree between RCT data and
RWE for SGLT2i therapies—reflecting the dif-
ferent patient populations—the trends in CVD
outcomes are similar and consistent [95].
Initial insights from the EMPRISE study,
assessing the real-world efficacy in reducing
HHF in people with T2DM (with or without
existing CVD) with empagliflozin against DPP-4
inhibitors, have shown a 44% reduction in
favour of the SGLT2i treatment [96]. As data
emerge from routine practice, particularly from
studies comparing active treatment arms, HCPs
will have a greater evidence base from which to
assess and support the management of people
with T2DM, considering future CVD outcomes.
PRIMARY AND SECONDARY
PREVENTION: WHEN MIGHT
INITIATION OF AN SGLT2I THERAPY
PROVIDE BENEFIT?
Several trials have now released data for people
both with established pre-existing disease and
for people with no previous established symp-
tomatic CVD, but with multiple risk factors. The
benefits of SGLT2i treatment are robustly sup-
ported in secondary prevention of CVD and HF,
with an increasing wealth of evidence demon-
strating significant benefits in people with no
established CVD or HF [50–54, 56, 59, 85, 97].
A recent meta-analysis across the three pub-
lished SGLT2i CVOT trials (EMPA-REG, CAN-
VAS and DECLARE-TIMI 58) provided further
support for the benefits of SGLT2i treatment in
patients with existing CVD; however, it
observed no role in reducing MACE in those
without pre-existing CVD, and noted more
emphasis on HF outcomes [97]. In terms of
reduction of MACE, there was an overall risk
reduction of 14% (HR 0.86; 95% CI 0.80–0.93)
in patients with established CVD, but no
improvement (HR 1.00; 95% CI 0.87–1.16) in
patients with risk factors only. Reduction in
composite HHF and CVD favoured SGLT2i
At a glance: Summary of different patient populations in the RWE studies described.
As with the RCTs for SGTL2i outcomes, the RWE studies also had different 
proportions of participants with established CVD included in their analyses, after 
propensity score or cohort matching [53-56, 86].
- In EASEL, all participants had established CVD [56].
- In CVD-REAL, 13% of matched participants had established CVD [53].
- In CVD-REAL 2, 27% of matched participants had established CVD [54].
- In CVD-REAL Nordic, 23% of matched participants had established CVD [94].
- In OBSERVE 4-D, 30% of matched participants had established CVD [55].
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treatment over placebo in people with estab-
lished CVD (HR 0.76; 95% CI 0.69–0.84) and
without established disease but multiple risk
factors (HR 0.84; 95% CI 0.69–1.01; p for inter-
action 0.41; Fig. 5). The Committee notes that
the findings for this composite endpoint were
most likely driven by a reduction in HHF.
Reduction of MACE appeared to be indepen-
dent of renal function. However, benefits in HF
were greater in people with relatively reduced
renal function [97].
It is the opinion of the Improving Diabetes
Steering Committee that for people with T2DM
and risk factors for CVD, regardless of the
presence of established CVD or HF, that the
early initiation of an SGLT2i treatment provides
people with T2DM with an optimum manage-
ment strategy by reducing hyperglycaemia,
aiding weight loss and lowering systolic BP.
Fig. 4 Overview of trial population and selected cardio-
vascular endpoints in real-world evidence studies
[53–56, 94]. This ﬁgure reports selected outcomes from
four trials and is not a head-to-head trial outcome. CI
conﬁdence interval, CVD cardiovascular disease, DPP-4i
dipeptidyl peptidase-4 inhibitor, HF heart failure, HHF
hospitalisation for heart failure, HR hazard ratio, oGLD
other glucose-lowering drug
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Fig. 5 SGLT2i treatment efﬁcacy in people both with and
without established CVD or HF [97]. a Meta-analysis of
MACE outcomes stratiﬁed by presence of established
CVD. b Meta-analysis of HHF and CV death stratiﬁed by
presence of established CVD. c Meta-analysis of HHF and
CV death stratiﬁed by history of HF. Adapted with
permission from Zelniker et al. [97]
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HOW IS THIS EVOLVING EVIDENCE-
BASE BEING REFLECTED
IN PRACTICAL GUIDELINES?
A role for SGLT2i treatments in the manage-
ment of T2DM is acknowledged in the current
National Institute for Health and Care Excel-
lence (NICE) clinical guidelines on T2DM
management [98]. However, triple therapy
option in these guidelines is limited to use with
metformin and a sulfonylurea. Current NICE
guidelines do not yet offer advice on selection
of T2DM treatment according to CVD risk [99].
Recent Scottish Intercollegiate Guidelines Net-
work (SIGN) guidelines recommend considering
the evidence base for initiation of an SGLT2i or
GLP-1 receptor agonist for patients with exist-
ing CVD, but do not offer advice on the specific
selection of these drugs [100].
The American Diabetes Association (ADA)/
European Association for the Study of Diabetes
(EASD) panel has issued a consensus statement
on the use of anti-diabetic medicines when
considering outcomes beyond glycaemic con-
trol alone (ASCVD, HF, CKD, weight manage-
ment and control of hypoglycaemia; Fig. 6)
[101]. This consensus represents a welcome
advance in personalising T2DM management.
However, the Improving Diabetes Steering
Committee recognises that the ADA/EASD
position statement has limitations in that it
may be difficult for clinicians to decide which
disease category has priority. For example, in a
patient with both HF and ASCVD, it is difficult
to assess whether an SGLT2i or a GLP-1 RA
should be prescribed, especially with an absence
of supportive evidence, in which case options
should be discussed with people with T2DM
and a decision made on an individual basis. The
Committee suggests that in the period before
NICE guidelines are updated to reflect the CVD
and HF considerations of treatment selection,
wider implementation of the ADA/EASD con-
sensus would be of value in improving
outcomes.
Local guidelines may not always reflect
emerging data; moreover, they need consider-
able resource allocation to be updated, and
updates are even more challenging in rapidly
evolving treatment areas. It would therefore be
valuable to have broader and more accessible
advice for the use of SGLT2i treatments in
people with T2DM at risk of CVD. This
Improving Diabetes Steering Committee con-
sensus paper aims to offer practical advice to
HCPs in the selection of treatment as an add-on
to metformin and seeks to facilitate personali-
sation of medicine for people with T2DM and at
risk of developing CVD.
OVERCOMING TREATMENT
COMFORT IN TYPE 2 DIABETES
MANAGEMENT: AND PREPARING
FOR NEW TREATMENT
APPROACHES
It is well understood that there is significant
‘inertia’ in the management of people with
T2DM, with treatment escalation often taking
many years—leaving people with suboptimal
glucose control [102]. As HCPs look beyond a
glucocentric management strategy for people
with T2DM at risk of CVD there are several
challenges to adopting new treatment approa-
ches, including a lack of familiarity with newer
agents, limited prescribing options through
local formulary practice and a lack of flexibility
within prevailing local guidelines. Expanding
the physician knowledge base and increasing
awareness in routine practice of the perfor-
mance of newer therapeutic options is key in
overcoming these barriers. Demonstrating the
efficacy of SGLT2i therapies in CVD outcomes
in the context of other common CVD drugs
may help physicians appreciate the magnitude
of CVD benefit offered by this class.
A recent study noted that the number nee-
ded to treat (NNT) to see a benefit in all-cause
death compared favourably for empagliflozin
against simvastatin or ramipril [103]. When
published data for CV death, HHF and all-cause
mortality were examined in a non-head-to-head
illustrative comparison, SGLT2i therapies have
favourable HF reductions compared with
angiotensin-converting enzyme inhibitors
(ACEi) and angiotensin receptor blockers
(ARBs), with each drug compared to placebo
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Fig. 6 ADA/EASD consensus on treatment selection in T2DM when considering CVD or renal outcomes. Adapted with
permission from [101]
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(Fig. 7). Given the comfort with which HCPs
consider the prescription of these routine drugs,
the Committee notes that early and appropriate
intervention with SGLT2i therapies may yield
economical and clinically meaningful benefits
in people with T2DM at risk of CVD.
PRACTICAL ADVICE: THE USE
OF SGLT2I TREATMENT IN PEOPLE
RECEIVING DIURETICS
There is opinion that SGLT2i agents are broadly
appropriate to use alongside diuretics, with
routine monitoring of renal function, especially
in patients receiving loop diuretics [104]. Cur-
rent prescribing advice notes that empagliflozin
may increase the diuretic effect of thiazide and
loop diuretics and may increase the risk of
dehydration and hypotension [67], and cana-
gliflozin and dapagliflozin are not recom-
mended for use in patients receiving loop
diuretics [66, 68].
An analysis of the EMPA-REG OUTCOME
trial suggests that the significant benefits of
empagliflozin on HHF were seen in people not
receiving diuretics (including loop diuretics) at
baseline, but not in those that were [105]. This
suggests that the diuretic action of SGLT2i
agents may play a key role in the improvements
these agents provide on HF outcomes [105]. A
sensitivity analysis noted that empagliflozin
had a positive effect on 3P-MACE in patients
either using loop diuretics (HR 0.91; 95% CI
0.67–1.23) or not (HR 0.84; 95% CI 0.71–1.00)
at baseline, and similar significant reduction in
CV death in those receiving loop diuretics (HR
0.60; 95% CI 0.40–0.90) or not (HR 0.63; 95% CI
0.48–0.82) at baseline [85].
Although the primary pharmacological
action of SGLT2i agents occurs in the proximal
convoluted tubule (the location of the SGLT2
transporter), it has been suggested that the
diuretic action that they induce could be a
secondary downstream effect of altered sodium
balance in the loop of Henle, meaning that
Fig. 7 Illustrative efﬁcacy of SGLT2i treatments in the reduction of CVD risks in the context of commonly used CVD
drugs
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SGLT2i treatments could be considered to act
similarly to loop diuretics [105]. A study in
healthy volunteers has demonstrated a mutual
adaptive synergy between a loop diuretic
(bumetanide) and dapagliflozin, suggesting that
SGLT2i medications may be helpful in HF
patients with resistance to loop diuretics [106].
A further, similar study examining the effects of
SGLT2 inhibition in combination with the loop
diuretic furosemide on diuresis, with the
hypothesis that SGLT2 inhibition may augment
the effects of loop diuretics, is ongoing [107].
If loop diuretic drugs (including SGLT2i
medications) are administered alone, sodium
reabsorption in the distal tubules of the
nephrons is enhanced in a compensatory man-
ner, limiting diuresis [105]. However, con-
comitant administration of loop diuretics with
thiazide diuretics, which act on the distal
tubules, may result in massive diuresis,
hypotension and/or dehydration [105]. For this
reason, HCPs initiating an SGLT2i therapy in a
person receiving a combination antihyperten-
sive therapy that includes a diuretic may choose
to reduce or discontinue loop or thiazide
diuretic before commencing the SGLT2i treat-
ment; this consideration is of particular impor-
tance in the elderly.
The Improving Diabetes Steering Committee
reiterates its previous practical advice in relation
to co-prescription of SGLT2i with diuretics [1]:
• Check electrolyte and renal function for all
individuals prescribed SGLT2i therapy. This
is particularly important for people on
diuretic therapies.
• Conduct routine electrolyte and renal func-
tion measurements, as appropriate for indi-
vidual circumstances, comorbidities and
concomitant medications, checking 1
month after initiation of an SGLT2i in
people receiving diuretics. A modest reduc-
tion in eGFR of 3–5 mL/min/1.73 m2 may be
expected following the initiation of SGLT2i
therapy [108], as is the case for other med-
ications such as ACEis.
• Consider reducing or stopping diuretic
medicines for treatment of oedema or hyper-
tension, especially if blood pressure is well
controlled.
• Review medicines regularly and de-escalate
therapy where possible, in line with NHS
Scotland 2018 polypharmacy guidance.
MAXIMISING BENEFITS
IN THE TREATMENT OF TYPE 2
DIABETES: BEYOND HBA1C
Treatment with SGLT2i medication has
demonstrated efficacy in attaining glycaemic
targets, for which the class is currently indicated
[66–68]. The SGLT2i class is associated with
weight loss and lowering of BP, no increase in
hypoglycaemia and, via a number of mecha-
nisms, has increasingly robust evidence for the
reduction of CVD, HF hospitalisation and CV
death, in people with and without pre-existing
CVD [50–56, 85, 97]. Although the evidence on
effects on overall mortality and ASCVD are still
evolving, there is a demonstrated class effect
showing benefit in HF. Treatment of T2DMwith
SGLT2 inhibition has been associated with sig-
nificant reduction in albuminuria and reduced
incidence of worsening albuminuria [62, 63].
SGLT2i treatments are well tolerated and
have a favourable risk–benefit profile for many
people with T2DM [1]. In practice, SGLT2i
therapies appear to have a meaningful impact,
with an NNT for several CVD outcomes similar
to those of commonly prescribed drugs for the
management and prevention of CVD [103].
As HCPs seek to personalise medicine for
people with T2DM, it is appropriate to not only
take a glucocentric approach. An approach of
‘treating the person, rather than a disease’ is of
particular importance in managing T2DM,
where multiple comorbidities are common.
Treating each condition in isolation may lead to
missed opportunities in improving overall out-
comes for people with T2DM.
The Improving Diabetes Steering Committee
suggests that SGLT2i therapies, for many people
with T2DM and at risk of CVD, may represent a
logical first escalation from metformin.
While glucose control remains the corner-
stone of diabetes management, including
selecting appropriate HbA1c targets and
aggressiveness of therapy in consultation with
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the patient, there are clearly outcome benefits
beyond attainment of glycaemic targets. It is
prudent therefore to consider the CVD risk
factors people with T2DM may have and then
consider treatment options that take these fac-
tors into account. This is important considering
the shared risk factors, particularly elevated
blood pressure, dyslipidaemia and obesity, for
developing CVD and T2DM.
SUMMARY AND PRACTICAL
CONSIDERATIONS
Recent evidence from CVOTs and real-world
studies provides robust support for the initia-
tion of SGLT2i medication in people with
T2DM and who either have established CVD or
are at risk of developing CVD, and HF in par-
ticular, or at risk of renal decline and progres-
sion into CKD. It has been demonstrated that
SGLT2i treatment in T2DM is efficacious in
reducing HbA1c and is well tolerated. In addi-
tion, SGLT2i treatment has secondary benefits
in terms of weight loss and lowering BP and has
minimal risk of increased incidence of
hypoglycaemia.
In selecting efficacious treatment for people
with T2DM and risk of CVD, the ADA/EASD
consensus statement notes that both SGLT2i
and GLP-1 RA interventions may be
appropriate, and recommend determining the
existence of established CVD, or the probable
risk of developing CVD or CKD. In people with
T2DM and established ASCVD, either a GLP-1
RA or SGLT2 inhibitor, with demonstrated effi-
cacy in improving CV outcomes, can be selec-
ted, post metformin. Where the risk of
developing CKD or HF is the HCP’s main con-
cern, the initiation of SGLT2i therapy is rec-
ommended. If SGLT2i treatment is not tolerated
or not appropriate (the patient has an eGFR
outside of the licensed range, for example), then
a GLP-1 RA with demonstrated CV outcome
benefit should be used [101].
Here, the Improving Diabetes Steering
Committee provides practical advice on the use
of SGLT2i treatment in four major groups of
people with T2DM: people with established
CVD, people at high risk for developing CVD,
people at lower risk of developing CVD and frail
people. Level of evidence was graded according
to ADA standards (Table 1). A simple ‘traffic
light’ approach to clinical considerations in
these populations is provided in Table 2.
In people with T2DM and established CVD,
SGLT2i treatment provides clear benefits in
reduction of adverse CVD outcomes. Unless
contraindicated, the Committee advises that
SGLT2i treatment is recommended as an oral
treatment of choice, in combination with life-
style and other glucose-lowering drugs as
Table 1 ADA evidence-grading system for ‘‘Standards of Medical Care in Diabetes’’ [109]
Level of
evidence
Description
A Clear evidence from well-conducted, generalisable RCTs that are adequately powered, including:
• Evidence from a well-conducted multicentre trial or meta-analysis that incorporated quality ratings in
the analysis
• Compelling non-experimental evidence
B Supportive evidence from well-conducted cohort studies
Supportive evidence from a well-conducted case-control study
C Supportive evidence from poorly controlled or uncontrolled studies
Conﬂicting evidence with the weight of evidence supporting the recommendation
E Expert consensus or clinical experience
Adapted from [109]
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appropriate, to treat these people. In people
with T2DM and inadequate glucose control, the
Committee recommends that an SGLT2i is
considered as an early and efficacious treatment
option. There is a paucity of RCT data describ-
ing the effects of SGLT2 inhibition on CVD
outcomes in patients with well-controlled glu-
cose levels, because they were not typically
enrolled in the pivotal trials. However, in peo-
ple with T2DM and established CVD, HCPs may
wish to consider the potential CV benefits of
SGT2i treatment when reviewing a patient’s
management and discuss options for main-
taining glycaemic control while taking into
account comorbid CVD progression.
In people with T2DM and a high risk for
CVD, benefits in terms of MACE were demon-
strated in CANVAS but not in DECLARE-TIMI
58. However, there were significant reductions
in HHF and composites of HF and CV death in
both trials; thus, outcomes for people in this
stratum are optimised with SGLT2i treatment.
Unless contraindicated, the Committee advises
that SGLT2is are considered, in combination
with lifestyle and other glucose-lowering drugs
as appropriate, as adjunctive treatment to
improve glucose control and reduce risk of HF
and CVD.
In people with T2DM and a lower risk for
CVD, there is less robust evidence available
from the trials and studies presented in this
paper. However, it is well accepted that T2DM is
an independent risk factor for the development
of CVD. In addition, lifestyle factors that con-
tribute to the development of T2DM are risk
factors for the development of CVD. The Com-
mittee advises that for people for whom the
HCP can see benefit—in terms of glycaemic
control, weight loss, lower blood pressure—that
SGLT2i treatment may play a preventative role
Table 2 Clinical considerations for the management of CVD risk using SGLT2i therapies in people with T2DM
[1, 42–48, 57–59, 77, 78, 80, 81, 86]
CVD cardiovascular disease, DKA diabetic ketoacidosis, eGFR estimated glomerular ﬁltration rate, HF heart failure, MACE
major adverse cardiovascular events, T2DM type 2 diabetes mellitus
*SGLT2i therapies may be initiated in people with eGFR 60 mL/min/1.73 m2. Individuals already treated with canagliﬂozin
or empagliﬂozin who demonstrate renal decline may continue treatment until eGFR reaches\ 45 mL/min/1.73 m2
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for future HF, while providing efficacious T2DM
treatment in the immediate setting. Recent
RWE appears to demonstrate HF benefits in
patients without established CVD. SGLT2i
therapy may also be considered for people at
risk of developing CKD, with data supporting
efficacy in preventing the worsening of loss of
renal function.
In frail people with T2DM, the role of SGLT2i
treatment needs to be considered with care. For
many of these people, renal impairment will be
the main area of concern for both initiation and
appropriate discontinuation. For frail people,
any secondary effects of weight loss and lower-
ing of blood pressure may be undesirable and
must be considered in the personalisation of
treatment. The implications of the diuretic
action of SGLT2i treatment should be consid-
ered when assessing the appropriate treatment
and comfort of frail people, especially those
with impaired continence. The Committee
notes that for frail individuals that are suited to
initiation of an SGLT2i treatment, the benefits
in HF and MACE outcomes, in an anti-diabetes
treatment option that does not increase the risk
of hypoglycaemia, may be of value in the opti-
misation of treatment.
The Improving Diabetes Steering Committee
awaits forthcoming evidence for SGLT2i ther-
apy, particularly in terms of further elucidation
of CVD benefits in different patient populations
(such as the small group of people with T2DM
but without CV risk factors [hypertension, dys-
lipidaemia or smoking] other than diabetes) and
in terms of renal benefits. The Committee looks
forward to providing further evidence-based
advice to primary care HCPs in future updates.
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